Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446257 · ClinicalTrials.gov registry record · Early Phase 1
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT07446257: Clinical Trial Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
NCT07446257 is a Early Phase 1 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 60 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07446257, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Primary Outcome
Safety is measured as the proportion of participants who experience a treatment-related delay in the planned surgical resection, defined as surgery occurring more than 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)
Interventions
- DRUG Cadonilimab
- DRUG ateganosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2030-09-01 |
| Phase | Early Phase 1 |
What is known before NCT07446257 opens enrollment
NCT07446257 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 2 interventions - of which Cadonilimab is the first listed.
NCT07446257 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07446257 about?
NCT07446257 is a clinical study titled "THIO and Cadonilimab in Resectable Hepatocellular Carcinoma". The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
What is the current status of trial NCT07446257?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2026-06-29. Estimated completion is 2030-09-01.
What interventions are being tested in trial NCT07446257?
The interventions under investigation include: Cadonilimab (DRUG), ateganosine (DRUG).
Who is sponsoring clinical trial NCT07446257?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07446257's enrollment target sits among peer trials
60 403rd of 2000 higher than 1,564 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI